| LECOMTE, Thierry |
RePERSO, NCT04874207: Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients with Metastatic Colorectal Cancer Treated with REgorafenib |
|
|
| Active, not recruiting | 4 | 110 | Europe | Regorafenib | Rennes University Hospital | Colorectal Cancer Metastatic | 06/25 | 12/25 | | |
| Active, not recruiting | 3 | 792 | Europe | Geriatrician Intervention | Institut Bergonié, Ministry of Health, France | Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer, Ovarian Cancer, Lymphoma | 12/23 | 03/26 | | |
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA |
|
|
| Active, not recruiting | 3 | 507 | Europe, RoW | Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid | Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group | OESOPHAGO-GASTRIC CARCINOMA | 12/25 | 12/25 | | |
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over |
|
|
| Recruiting | 3 | 774 | Europe | LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine | Federation Francophone de Cancerologie Digestive | Colonic Adenocarcinoma | 12/24 | 08/25 | | |
| Active, not recruiting | 2 | 99 | Europe | MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG | Anal Cancer | 02/23 | 12/24 | | |
NCT04894123: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients |
|
|
| Terminated | 2 | 1 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin | GERCOR - Multidisciplinary Oncology Cooperative Group, Servier | Colorectal Adenocarcinoma, Oesogastric | 02/23 | 02/23 | | |
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. |
|
|
| Active, not recruiting | 2 | 307 | Europe | Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Metastatic Pancreatic Adenocarcinoma | 07/23 | 12/24 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Active, not recruiting | 2 | 177 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 12/24 | 12/25 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
| Active, not recruiting | 2 | 140 | Europe | LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France | Pancreatic Cancer | 12/28 | 12/28 | | |
NCT03694938: Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients |
|
|
| Recruiting | N/A | 200 | Europe | Magnetic resonance imaging | Poitiers University Hospital | Metastatic Colon Cancer | 02/30 | 02/30 | | |
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study |
|
|
| Recruiting | N/A | 1350 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Biliary Tract Cancer | 06/30 | 06/40 | | |
| AUBOURG, Alexandre |
PRIMER, NCT03596476: Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy |
|
|
| Recruiting | N/A | 330 | Europe | Upper gastrointestinal (GI) endoscopy, Wireless pH monitoring, Post prandial esophageal High Resolution Impedance Manometry, pH-impedance monitoring | Hospices Civils de Lyon | Gastro-esophageal Reflux Disease | 05/27 | 05/27 | | |
| Maruani, Annabel |
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata |
|
|
| Recruiting | 3 | 595 | Europe, Canada, Japan, US, RoW | Baricitinib, LY3009104, Placebo | Eli Lilly and Company | Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical | 09/24 | 08/29 | | |
| Recruiting | 2 | 12 | Europe | Sirolimus Oral Liquid Product 1mg/mL, Experimental treatment | University Hospital, Tours | Lingual Microcystic Lymphatic Malformations | 02/25 | 07/25 | | |
SESAM, NCT05577754: Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients with Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) |
|
|
| Recruiting | 2 | 20 | Europe | Alpelisib (BYL719), Matching placebo, Optional lumbar puncture + blood sample | Centre Hospitalier Universitaire Dijon, Novartis Pharmaceuticals | Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) | 03/27 | 03/27 | | |
NCT04451902: COVID-19 and Rare Skin Diseases European Observational Study During an Epidemic |
|
|
| Recruiting | N/A | 80 | Europe, RoW | | Imagine Institute | Rare Diseases | 04/22 | 12/22 | | |
| Recruiting | N/A | 250 | Europe | Questionnaire | University Hospital, Tours, INSERM UMR 1246 SPHERE | Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance, Psychological Well-Being, Social Segregation | 12/25 | 12/25 | | |
| Recruiting | N/A | 900 | Europe | | Institut National de la Santé Et de la Recherche Médicale, France | Inherited Epidermolysis Bullosa, Ichthyosis, Ectodermal Dysplasia, Incontinentia Pigmenti, Neurofibromatosis Type 1, Albinism, Pemphigus, Mucous Membrane Pemphigoid, Palmoplantar Keratoderma | 03/27 | 03/27 | | |
COVER, NCT04352036: Constitution of a Prospective Cohort of Patients With Acute Suppurative Hidrosadenitis Followed in the Great West: the Cohort (Verneuil Cohort) |
|
|
| Recruiting | N/A | 465 | Europe | no interventional study | Nantes University Hospital | Acute Hidrosadenitis | 02/30 | 02/30 | | |
| Moussata, ffa |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
ENDOBARRETT, NCT04867590: A Study Comparing the Effectiveness of EndoRotor Versus Radiofrequency in Treating Barrett's Esophagus |
|
|
| Recruiting | N/A | 140 | Europe | Endorotor, Radiofrequency | University Hospital, Angers | Barrett Esophagus, Dysplasia | 03/26 | 05/27 | | |
| Recruiting | N/A | 600 | Europe | Colonoscopy under hypnosis | University Hospital, Tours | Colorectal (Colon or Rectal) Cancer | 02/25 | 02/25 | | |
| Fauchier, Laurent |
DILEMMA, NCT05373940: Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 75 Years |
|
|
| Recruiting | N/A | 730 | Europe | ICD implantation, No ICD implantation | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France | Heart Failure, Primary Prevention of Sudden Cardiac Death, Implantable Cardioverter Defibrillator | 05/30 | 05/30 | | |
| Salamé, Ephrem |
METALAP, NCT04163887: Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases |
|
|
| Recruiting | N/A | 340 | Europe | hepatectomy | Institut Mutualiste Montsouris, Ministry of Health, France, National Cancer Institute, France | Liver Metastasis Colon Cancer, Postoperative Complications | 04/23 | 01/26 | | |
| GEORGESCOU, Gabriella |
| Recruiting | N/A | 340 | Europe | | Institut National de la Santé Et de la Recherche Médicale, France | Ehlers-Danlos Syndrome, Vascular Type | 12/23 | 12/23 | | |
